837 related articles for article (PubMed ID: 22208975)
1. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
[TBL] [Abstract][Full Text] [Related]
2. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
3. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
4. Ductal carcinoma in situ--the influence of the radiotherapy boost on local control.
Wong P; Lambert C; Agnihotram RV; David M; Duclos M; Freeman CR
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e153-8. PubMed ID: 21664063
[TBL] [Abstract][Full Text] [Related]
5. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience.
Sahoo S; Recant WM; Jaskowiak N; Tong L; Heimann R
Breast J; 2005; 11(4):242-7. PubMed ID: 15982389
[TBL] [Abstract][Full Text] [Related]
6. Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage.
Monteau A; Sigal-Zafrani B; Kirova YM; Fourchotte V; Bollet MA; Vincent-Salomon A; Asselain B; Salmon RJ; Fourquet A
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1021-8. PubMed ID: 19386441
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
[TBL] [Abstract][Full Text] [Related]
8. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
; ; Bijker N; Meijnen P; Peterse JL; Bogaerts J; Van Hoorebeeck I; Julien JP; Gennaro M; Rouanet P; Avril A; Fentiman IS; Bartelink H; Rutgers EJ
J Clin Oncol; 2006 Jul; 24(21):3381-7. PubMed ID: 16801628
[TBL] [Abstract][Full Text] [Related]
9. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy.
Ciervide R; Dhage S; Guth A; Shapiro RL; Axelrod DM; Roses DF; Formenti SC
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e159-64. PubMed ID: 22579378
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
11. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
12. HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy.
Noh JM; Lee J; Choi DH; Cho EY; Huh SJ; Park W; Nam SJ; Lee JE; Kil WH
Breast; 2013 Oct; 22(5):894-7. PubMed ID: 23643805
[TBL] [Abstract][Full Text] [Related]
13. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of breast cancer patients with triple negative receptor status treated with accelerated partial breast irradiation.
Wilkinson JB; Reid RE; Shaitelman SF; Chen PY; Mitchell CK; Wallace MF; Marvin KS; Grills IS; Margolis JM; Vicini FA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e159-64. PubMed ID: 21345613
[TBL] [Abstract][Full Text] [Related]
16. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status.
Wilder RB; Curcio LD; Khanijou RK; Eisner ME; Kakkis JL; Chittenden L; Agustin J; Lizarde J; Mesa AV; Macedo JC; Ravera J; Tokita KM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):799-803. PubMed ID: 20869583
[TBL] [Abstract][Full Text] [Related]
17. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study.
Benitez PR; Streeter O; Vicini F; Mehta V; Quiet C; Kuske R; Hayes MK; Arthur D; Kuerer H; Freedman G; Keisch M; Dipetrillo T; Khan D; Hudes R
Am J Surg; 2006 Oct; 192(4):427-33. PubMed ID: 16978943
[TBL] [Abstract][Full Text] [Related]
18. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
[TBL] [Abstract][Full Text] [Related]
19. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.
Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A
Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516
[TBL] [Abstract][Full Text] [Related]
20. Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary?
Yerushalmi R; Sulkes A; Mishaeli M; Neumann A; Dinerman M; Sulkes J; Rizel S; Yarom N; Gutman H; Fenig E
Neoplasma; 2006; 53(6):507-10. PubMed ID: 17167720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
